{"filing":{"accession_number":"0000926617-26-000037","cik":"0000926617","ticker":"AWHL","company_name":"Aspira Women's Health Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"awhl-20260520x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000037/awhl-20260520x8k.htm"},"events":[{"id":8937,"run_id":7843,"accession_number":"0000926617-26-000037","anchor_item_number":"1.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Aspira entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation for biomedical research and development, with a $125,000 partnering fee over five years. While this is a material definitive agreement disclosed under Item 1.01, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), and the collaboration arrangement with fixed fees and research focus does not fit the more specific event categories. The agreement is material to investors as it represents a significant strategic partnership and commitment of capital.","company_name":"Aspira Women's Health Inc.","ticker":"AWHL","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1392,"accession_number":"0000926617-26-000037","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Aspira entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation for biomedical research and development, with a $125,000 partnering fee over five years. While this is a material definitive agreement disclosed under Item 1.01, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), and the collaboration arrangement with fixed fees and research focus does not fit the more specific event categories. The agreement is material to investors as it represents a significant strategic partnership and commitment of capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:06.476002+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1392,"accession_number":"0000926617-26-000037","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Aspira entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation for biomedical research and development, with a $125,000 partnering fee over five years. While this is a material definitive agreement disclosed under Item 1.01, it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control), and the collaboration arrangement with fixed fees and research focus does not fit the more specific event categories. The agreement is material to investors as it represents a significant strategic partnership and commitment of capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:06:06.476002+00:00","company_name":"Aspira Women's Health Inc.","ticker":"AWHL","filing_date":"2026-05-26"}]}